eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | neurofibromatosis 2 |
| Comorbidity | C0027809|schwannoma |
| Sentences | 10 |
| PubMedID- 24311643 | Methods: we conducted a single-institution, prospective, 2-stage, open-label phase ii study to estimate the response rate to everolimus in neurofibromatosis type 2 (nf2) patients with progressive vestibular schwannoma (vs). |
| PubMedID- 21817944 | Management strategy of vestibular schwannoma in neurofibromatosis type 2. |
| PubMedID- 22805104 | Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. |
| PubMedID- 26287269 | Factors influencing the growth rate of vestibular schwannoma in patients with neurofibromatosis type 2. |
| PubMedID- 26108240 | Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage. |
| PubMedID- 20736812 | We sought to determine the activity of erlotinib for progressive vestibular schwannoma (vs) associated with neurofibromatosis 2 (nf2). |
| PubMedID- 23453897 | We present a case of macrodactyly of the small finger associated with a digital nerve plexiform schwannoma in a patient with neurofibromatosis type 2. |
| PubMedID- 22844108 | This single-institution phase ii study was performed to estimate the response rate to lapatinib in neurofibromatosis type 2 (nf2) patients with progressive vestibular schwannoma (vs). |
| PubMedID- 23413263 | Loss of the merlin tumour suppressor causes abnormal de-differentiation and proliferation of schwann cells and formation of schwannoma tumours in patients with neurofibromatosis type 2. |
| PubMedID- 24335931 | Ipsilateral cochlear implantation after cochlear nerve preserving vestibular schwannoma surgery in patients with neurofibromatosis type 2. |
Page: 1